Provider Briefing: Catapres (Clonidine) Supply in 2026

As a prescriber, you've likely fielded calls from patients who can't fill their Clonidine prescriptions. The supply landscape for Catapres and generic Clonidine has shifted meaningfully over the past few years, and staying current helps you advise patients proactively and avoid gaps in care.

This briefing covers the current supply status, prescribing implications, available alternatives, and tools you can use to support patients navigating availability challenges.

Supply Timeline: How We Got Here

Understanding the timeline helps contextualize current availability:

• 2022: Boehringer Ingelheim issued a voluntary recall of Catapres brand tablets in the US due to quality concerns, followed by permanent discontinuation of the product. Generic Clonidine manufacturers absorbed the demand.
• 2023-2024: Intermittent supply disruptions for Clonidine transdermal patches (Catapres-TTS) as limited manufacturers struggled to meet demand. Generic oral tablet supply remained largely stable.
• December 2025: Clinect announced a shortage of Catapres 150 mcg tablets in international markets (notably Australia), projected through April 2026, due to manufacturing issues.
• 2026 (current): US generic Clonidine IR tablets are broadly available. Patch supply remains variable. Extended-release formulations (Kapvay, Nexiclon XR, Onyda XR) have mixed availability depending on manufacturer and strength.

Prescribing Implications

Several clinical considerations arise from the evolving supply picture:

Prescription Language Matters

Patients with legacy prescriptions written for "Catapres" with Dispense as Written (DAW) codes may face unnecessary fill failures. Review active prescriptions and consider rewriting for generic Clonidine to allow pharmacist flexibility. This simple step eliminates a common barrier.

Formulation Flexibility

When one formulation is unavailable, consider whether the patient's clinical needs can be met by an alternative delivery system:

• IR tablets → transdermal patch: Useful for patients with adherence challenges or GI absorption concerns. Note: patch delivers steady-state levels, but onset is slower (2-3 days to therapeutic levels). The 0.1 mg/day patch approximately replaces 0.1 mg oral BID.
• Patch → IR tablets: If patches are unavailable, convert based on the patch strength to equivalent divided oral doses.
• IR → ER formulations: Extended-release options (Kapvay, Nexiclon XR, Onyda XR) allow once-daily dosing. However, these are not AB-rated substitutes for IR Clonidine — a new prescription is required.

Taper and Transition Protocols

Remind patients and support staff that Clonidine must be tapered over 2-4 days when discontinuing. Abrupt cessation risks rebound hypertension, with reported cases of hypertensive encephalopathy, cerebrovascular accidents, and death. If transitioning to an alternative agent, overlap therapy during the taper period.

For detailed side effect and withdrawal information to share with patients, see: Catapres Side Effects: What to Expect.

Current Availability Picture

Cost and Access Considerations

Most patients will find generic Clonidine IR tablets affordable:

• With insurance: Typically Tier 1 preferred generic. Copays range from $0-$15.
• Without insurance: Retail ~$22 for 30 tablets (0.1 mg). With discount cards (GoodRx, SingleCare): $4-$10.
• Patches without insurance: $120-$200/month retail. Discount cards help less with patches.
• ER formulations: $170-$240 retail; $18-$24 with coupons.

For patients facing cost barriers, the Boehringer Ingelheim Cares Foundation Patient Assistance Program may help for eligible products. Generic Clonidine is also on most $4 generic lists at major retail pharmacies. A comprehensive savings guide for patients is available at: How to Save Money on Catapres.

Tools and Resources for Your Practice

Help your patients find their medication faster with these resources:

• Medfinder for Providers: medfinder.com/providers — Real-time pharmacy inventory search. Direct patients here or use it during the visit to identify pharmacies with Clonidine in stock.
• FDA Drug Shortage Database: accessdata.fda.gov — Official shortage listings and estimated resolution dates.
• ASHP Drug Shortages List: ashp.org — Continuously updated shortage information with clinical recommendations.

For practical guidance on helping patients navigate availability, see our provider guide: How to Help Your Patients Find Catapres in Stock.

Alternative Agents to Consider

When Clonidine is truly unavailable or a patient needs to transition, consider these alternatives based on indication:

For Hypertension

• Guanfacine (Tenex): Same drug class, once-daily dosing, less sedation. Most direct substitute.
• Methyldopa: Centrally acting; particularly useful in pregnancy-related hypertension.
• Consider first-line agents: ACE inhibitors, ARBs, calcium channel blockers, or thiazide diuretics may be more appropriate per current guidelines if the patient was on Clonidine as monotherapy.

For ADHD

• Guanfacine ER (Intuniv): FDA-approved for ADHD ages 6-17. Once-daily non-stimulant option.
• Atomoxetine (Strattera): Non-stimulant SNRI; different mechanism but another non-controlled option.

For Opioid/Substance Withdrawal

• Lofexidine (Lucemyra): FDA-approved specifically for opioid withdrawal symptom management. Alpha-2 agonist similar to Clonidine but with a labeled indication.
• Buprenorphine-based protocols: For patients in MAT programs.

For a complete alternatives overview to share with patients: Alternatives to Catapres.

Looking Ahead

The generic Clonidine tablet market in the US remains robust with multiple manufacturers. The international manufacturing issues affecting brand Catapres are expected to resolve by mid-2026. Patch supply will likely remain variable due to the limited number of manufacturers.

Proactive steps — rewriting prescriptions for generic, discussing formulation alternatives, and directing patients to availability tools like Medfinder — can prevent care gaps before they happen.

Final Thoughts

The Clonidine supply situation in 2026 is manageable with awareness and planning. Most patients can be served by generic IR tablets, which remain widely available and affordable. For those who need patches or ER formulations, a combination of formulation flexibility, proactive prescription management, and patient-facing tools like Medfinder for Providers will keep your patients on track.

For a patient-facing version of this update, direct patients to: Catapres Shortage Update: What Patients Need to Know in 2026.